These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 9423307

  • 1. [Impact of androgen deprivation prior to radical prostatectomy for T1, T2 prostate cancer on the likelihood of curative surgery].
    Hachiya T, Kobayashi K, Ichinose T, Ishida H, Okada K.
    Nihon Hinyokika Gakkai Zasshi; 1997 Nov; 88(11):936-44. PubMed ID: 9423307
    [Abstract] [Full Text] [Related]

  • 2. [8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].
    Tabata K, Satoh T, Matsumoto K, Fujita T, Irie A, Iwamura M, Yanagisawa N, Matsuda D, Muramoto M, Kadowaki K, Suyama K, Shoji K, Koh H, Kawakami T, Okayasu I, Egawa S, Baba S.
    Nihon Hinyokika Gakkai Zasshi; 2006 Jul; 97(5):712-8. PubMed ID: 16898594
    [Abstract] [Full Text] [Related]

  • 3. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
    Hara I, Miyake H, Hara S, Gotoh A, Eto H, Arakawa S, Kamidono S.
    Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127
    [Abstract] [Full Text] [Related]

  • 4. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer.
    Dalkin BL, Ahmann FR, Nagle R, Johnson CS.
    J Urol; 1996 Apr; 155(4):1357-60. PubMed ID: 8632574
    [Abstract] [Full Text] [Related]

  • 5. [Neoadjuvant endocrine therapy prior to nerve-sparing radical prostatectomy in patients with stage T2 prostatic cancer].
    Ueda T, Nakatsu H, Isaka S, Shimazaki J.
    Nihon Hinyokika Gakkai Zasshi; 1995 Jul; 86(7):1266-71. PubMed ID: 7637243
    [Abstract] [Full Text] [Related]

  • 6. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer.
    Witjes WP, Schulman CC, Debruyne FM.
    Urology; 1997 Mar; 49(3A Suppl):65-9. PubMed ID: 9123739
    [Abstract] [Full Text] [Related]

  • 7. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
    Tiguert R, Rigaud J, Lacombe L, Laverdière J, Fradet Y.
    J Urol; 2003 Aug; 170(2 Pt 1):447-50. PubMed ID: 12853796
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y, Akaza H, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y, Prostate Cancer Study Group.
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
    Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA.
    Urology; 2001 Feb; 57(2):281-5. PubMed ID: 11182337
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
    Cher ML, Shinohara K, Breslin S, Vapnek J, Carroll PR.
    Br J Urol; 1995 Jun; 75(6):771-7. PubMed ID: 7542137
    [Abstract] [Full Text] [Related]

  • 15. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR, Betancourt JE.
    Mol Urol; 2000 Jun; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [Abstract] [Full Text] [Related]

  • 16. [Prognostic factors in patients with prostatic cancer treated with neoadjuvant hormonal therapy and radical prostatectomy].
    Villavicencio Mavrich H, Chéchile Toniolo G, Salinas Duffo D, Muñoz Plaza J, Sorraca Ibáñez YJ.
    Arch Esp Urol; 1996 Oct; 49(8):797-806. PubMed ID: 9065276
    [Abstract] [Full Text] [Related]

  • 17. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
    Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S, Canadian Uro-Oncology Group.
    J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
    [Abstract] [Full Text] [Related]

  • 18. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure.
    Meyer F, Moore L, Bairati I, Lacombe L, Têtu B, Fradet Y.
    J Urol; 1999 Dec; 162(6):2024-8. PubMed ID: 10569561
    [Abstract] [Full Text] [Related]

  • 19. Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results.
    Abbas F, Kaplan M, Soloway MS.
    Br J Urol; 1996 Mar; 77(3):423-8. PubMed ID: 8814850
    [Abstract] [Full Text] [Related]

  • 20. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA, Katcher J, Levin HS, Klein EA.
    Int J Radiat Oncol Biol Phys; 1997 Mar 15; 37(5):1043-52. PubMed ID: 9169811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.